









Markets
/
Stocks
/
nasdaq-srzn
/

Surrozen Inc

SRZN

27.400USD

-0.600-2.14%

Close 03/30, 16:00（ET）Quotes delayed by 15 min

63.98MMarket Cap

LossP/E TTM



Surrozen Inc

27.400

-0.600-2.14%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Surrozen Inc

Currency: USD Updated: 2026-03-27

Key Insights

Surrozen Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 60 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 38.75.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Surrozen Inc's Score

Industry at a Glance

Industry Ranking

60 / 391

Overall Ranking

169 / 4542

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Surrozen Inc Highlights

StrengthsRisks

Surrozen, Inc. is a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. The Company is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with a focus in ophthalmology. Its product candidates include SZN-8141 for Retinal Diseases, SZN-8143 for Retinal Diseases, SZN-113 for Fuchs’ Endothelial Corneal Dystrophy and Geographic Atrophy, and SZN-413 for Retinal Diseases. SZN-8141 combines Frizzled 4 (Fzd4) agonism and Vascular Endothelial Growth Factor (VEGF) antagonism which has the potential to provide benefits over treatment with single agents for Diabetic Macular Edema (DME) and neovascular Age Related Macular Degeneration (wet AMD). SZN-8143 combines Fzd4 agonism, VEGF antagonism, and interleukin-6 (IL-6) antagonism which may have benefits over single agents for treatment of DME/wet AMD/uveitic macular edema. SZN-413 is a bi-specific antibody, designed using its SWAP technology.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Undervalued

The company’s latest PE is -0.89, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 7.28M shares, increasing 5.11% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 22.63K shares of this stock.

Analyst Rating

Based on 4 analysts

Buy

Current Rating

38.750

Target Price

+38.39%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Surrozen Inc is 5.71, ranking 328 out of 391 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.71

Change



Financials

6.33

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.61

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.84

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.70

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.08

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Surrozen Inc's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Surrozen Inc is 6.59, ranking 249 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.89, which is -70.72% below the recent high of -0.26 and -139.15% above the recent low of -2.14.

Score

Industry at a Glance

Previous score

6.59

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 60/391

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

The current earnings forecast score of Surrozen Inc is 8.67, ranking 72 out of 391 in the Biotechnology & Medical Research industry. The average price target is 37.00, with a high of 42.00 and a low of 32.00.

Score

Industry at a Glance

Previous score

8.50

Change

0.17

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 4 analysts

Buy

Current Rating

38.750

Target Price

+34.08%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

548

Total

Median

Average

Company name

Ratings

Analysts

Surrozen Inc

SRZN

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

110

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Surrozen Inc is 9.50, ranking 6 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 31.19 and the support level at 25.02, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.25

Change

0.25

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.124

Buy

RSI(14)

55.780

Neutral

STOCH(KDJ)(9,3,3)

75.031

Neutral

ATR(14)

2.214

Low Volatility

CCI(14)

133.799

Buy

Williams %R

33.111

Buy

TRIX(12,20)

0.133

Sell

StochRSI(14)

54.785

Sell

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

27.098

Buy

MA10

26.379

Buy

MA20

26.676

Buy

MA50

24.732

Buy

MA100

21.391

Buy

MA200

16.250

Buy

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Surrozen Inc is 7.00, ranking 85 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 84.95%, representing a quarter-over-quarter increase of 18.27%. The largest institutional shareholder is The Vanguard, holding a total of 319.24K shares, representing 3.72% of shares outstanding, with 363.35% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

The Column Group LP

1.85M

+1.99%

Millennium Management LLC

564.85K

+414.58%

VR Adviser, LLC

632.93K

StemPoint Capital LP

713.46K

+3.92%

Braidwell LP

140.00K

5AM Ventures

310.00K

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Surrozen Inc is 2.53, ranking 218 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 0.54. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.